Vaccines & Biologics

Tanzania has no domestic human vaccine manufacturing capacity, a gap exposed by every recent supply shock. The Government has prioritised vaccines and biologics for the highest level of structuring support, including green-lane approvals and offtake discussions through MSD and regional pooled procurement. This tier suits investors with established biologics platforms seeking an African manufacturing footprint.

Why this tier

• National priority: zero domestic human vaccine capacity
• Green-lane approvals and government-to-government offtake channels
• Regional pooled procurement access across EAC and SADC

Next steps

Review the regulatory pathway · See the incentive package

Submit EOI for this tier